# rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

> **NCT00275171** · PHASE2 · COMPLETED · sponsor: **Steen Bonnema** · enrollment: 90 (actual)

## Conditions studied

- Nodular Goiter

## Interventions

- **DRUG:** Recombinant human thyrotropin (Thyrogen)
- **DRUG:** recombinant human TSH
- **OTHER:** isotonic saline = placebo

## Key facts

- **NCT ID:** NCT00275171
- **Lead sponsor:** Steen Bonnema
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-09
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275171, "rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00275171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*